Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | COPS5 | Q92905 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 3/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2021765 | 0.86 | DHFR (0.43) | DHFRADORA1ADORA3TAAR1BACE1 | |
| SCHEMBL2018800 | 0.83 | DHFR (0.46) | DHFRADORA1ADORA3TAAR1ADORA2A | |
| SCHEMBL2026371 | 0.81 | HPSE (0.43) | DHFRADORA1BACE1ADORA2ATLR8 | |
| SCHEMBL2025901 | 0.77 | CYP19A1 (0.48) | DHFRADORA1ADORA2APOLB | |
| SCHEMBL2021991 | 0.76 | BACE1 (0.44) | ADORA1TAAR1BACE1ADORA2A | |
| SCHEMBL2022025 | 0.72 | ADORA2A (0.62) | DHFRADORA1BACE1ADORA2ATLR8 | |
| SCHEMBL2019846 | 0.68 | ALDH1A1 (0.48) | DHFRPOLBRAB9A | |
| SCHEMBL4148180 | 0.65 | BACE1 (0.74) | DHFRCOPS5BACE1NPC1RAB9A | |
| SCHEMBL2019661 | 0.64 | CYP1A2 (0.45) | ADORA1HTR2ATAAR1ADORA2ATLR8 | |
| SCHEMBL2018334 | 0.63 | ADORA2A (0.43) | ADORA1ADORA3ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329705-B2 | Substituted triazolo-pyrazine compounds | ARQULE, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160215-A1 | Substituted Triazolo-Pyrazine Compounds | MKI67, TP53, THPO | DHFR 49/4885COPS5 2682/4885ADORA1 2652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.